“Her appointment is a natural development for Cantargia as a maturing company with two product candidates in clinical trials and having recently transacted with an international pharmaceutical company,” says Chairman of the Board of Directors, Magnus Persson. “We are very confident that Hilde will be an inspiring and highly effective leader as we build on our deal with Otsuka to create value for all our stakeholders. We wish to thank Damian Marron for his highly productive leadership as Interim CEO during the last few months and look forward to continuing working with him in his capacity as independent director.”

Damian Marron, who assumed the role of Interim CEO in February 2025, will continue in his role as Non-Executive Director and resume the role of Chair of the Remuneration Committee of the Board of Cantargia.

Hilde Steineger

Dr Hilde Steineger currently serves as Chief Operating Officer and co-founder of NorthSea Therapeutic, a late-stage bio-pharmaceutical company with three clinical candidates. At NorthSea, she played a leading role in raising USD 155 million in Series A-C financing. Hilde also served as CEO of Staten Biotechnology, where she led a USD 480 million licensing deal with Novo Nordisk. Before to Joining Staten Biotechnology and NorthSea, Hilde was Head of Strategic Innovation Management in Nutrition and Health Division (EN) of BASF. Hilde has prior extensive experience in the intersection of business/finance and life science, both as a financial analyst covering life science stocks, as venture capitalist at a life science venture fund and as Head of Business Development at Pronova BioPharma. She has served on multiple Board of Directors, including Algeta ASA, Nordic Nanovector and Strongbridge Biopharma plc (listed on Nasdaq), Hilde has a PhD in medical biochemistry and a M.Sc. in molecular biology/biotechnology from the University of Oslo.

”I am thrilled to join Cantargia at this exciting stage of its development. The company’s focus on innovative antibody-based therapies targeting IL1RAP and its strategic partnership with Otsuka represent significant opportunities to advance impactful treatments. I look forward to contributing to Cantargia’s ongoing success and working with the team to create value for all stakeholders,” says Hilde Steineger.